🚀 VC round data is live in beta, check it out!
Autolus Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Autolus Therapeutics and similar public comparables like Immutep, Bicycle Therapeutics, Absci, PureTech Health and more.
Autolus Therapeutics Overview
About Autolus Therapeutics
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Founded
2018
HQ
Employees
647
Website
Sectors
Financials (LTM)
EV
$94M
Autolus Therapeutics Financials
Autolus Therapeutics reported last 12-month revenue of $89M and negative EBITDA of ($254M).
In the same LTM period, Autolus Therapeutics generated ($5M) in gross profit, ($254M) in EBITDA losses, and had net loss of ($252M).
Revenue (LTM)
Autolus Therapeutics P&L
In the most recent fiscal year, Autolus Therapeutics reported revenue of $10M and EBITDA of ($202M).
Autolus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $89M | XXX | $10M | XXX | XXX | XXX |
| Gross Profit | ($5M) | XXX | ($1M) | XXX | XXX | XXX |
| Gross Margin | (6%) | XXX | (13%) | XXX | XXX | XXX |
| EBITDA | ($254M) | XXX | ($202M) | XXX | XXX | XXX |
| EBITDA Margin | (287%) | XXX | (1997%) | XXX | XXX | XXX |
| EBIT Margin | (291%) | XXX | (2352%) | XXX | XXX | XXX |
| Net Profit | ($252M) | XXX | ($221M) | XXX | XXX | XXX |
| Net Margin | (285%) | XXX | (2181%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Autolus Therapeutics Stock Performance
Autolus Therapeutics has current market cap of $395M, and enterprise value of $94M.
Market Cap Evolution
Autolus Therapeutics' stock price is $1.49.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $94M | $395M | 0.0% | XXX | XXX | XXX | $-0.83 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAutolus Therapeutics Valuation Multiples
Autolus Therapeutics trades at 1.1x EV/Revenue multiple, and (0.4x) EV/EBITDA.
EV / Revenue (LTM)
Autolus Therapeutics Financial Valuation Multiples
As of March 18, 2026, Autolus Therapeutics has market cap of $395M and EV of $94M.
Equity research analysts estimate Autolus Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Autolus Therapeutics has a P/E ratio of (1.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $395M | XXX | $395M | XXX | XXX | XXX |
| EV (current) | $94M | XXX | $94M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 9.3x | XXX | XXX | XXX |
| EV/EBITDA | (0.4x) | XXX | (0.5x) | XXX | XXX | XXX |
| EV/EBIT | (0.4x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/Gross Profit | (18.4x) | XXX | (73.9x) | XXX | XXX | XXX |
| P/E | (1.6x) | XXX | (1.8x) | XXX | XXX | XXX |
| EV/FCF | (0.4x) | XXX | (0.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Autolus Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Autolus Therapeutics Margins & Growth Rates
Autolus Therapeutics' revenue in the last 12 month grew by 73%.
Autolus Therapeutics' revenue per employee in the last FY averaged $0.1M.
Autolus Therapeutics' rule of 40 is (214%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Autolus Therapeutics' rule of X is (105%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Autolus Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 73% | XXX | 650% | XXX | XXX | XXX |
| EBITDA Margin | (287%) | XXX | (1997%) | XXX | XXX | XXX |
| EBITDA Growth | (17%) | XXX | 29% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (214%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (105%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 154% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 128% | XXX | 1368% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 2367% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Autolus Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Immutep | XXX | XXX | XXX | XXX | XXX | XXX |
| Bicycle Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Absci | XXX | XXX | XXX | XXX | XXX | XXX |
| PureTech Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Nextbiomedical Co | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Autolus Therapeutics M&A Activity
Autolus Therapeutics acquired XXX companies to date.
Last acquisition by Autolus Therapeutics was on XXXXXXXX, XXXXX. Autolus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Autolus Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAutolus Therapeutics Investment Activity
Autolus Therapeutics invested in XXX companies to date.
Autolus Therapeutics made its latest investment on XXXXXXXX, XXXXX. Autolus Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Autolus Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Autolus Therapeutics
| When was Autolus Therapeutics founded? | Autolus Therapeutics was founded in 2018. |
| Where is Autolus Therapeutics headquartered? | Autolus Therapeutics is headquartered in United States. |
| How many employees does Autolus Therapeutics have? | As of today, Autolus Therapeutics has over 647 employees. |
| Who is the CEO of Autolus Therapeutics? | Autolus Therapeutics' CEO is Christian Itin. |
| Is Autolus Therapeutics publicly listed? | Yes, Autolus Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Autolus Therapeutics? | Autolus Therapeutics trades under AUTL ticker. |
| When did Autolus Therapeutics go public? | Autolus Therapeutics went public in 2018. |
| Who are competitors of Autolus Therapeutics? | Autolus Therapeutics main competitors are Immutep, Bicycle Therapeutics, Absci, PureTech Health. |
| What is the current market cap of Autolus Therapeutics? | Autolus Therapeutics' current market cap is $395M. |
| What is the current revenue of Autolus Therapeutics? | Autolus Therapeutics' last 12 months revenue is $89M. |
| What is the current revenue growth of Autolus Therapeutics? | Autolus Therapeutics revenue growth (NTM/LTM) is 73%. |
| What is the current EV/Revenue multiple of Autolus Therapeutics? | Current revenue multiple of Autolus Therapeutics is 1.1x. |
| Is Autolus Therapeutics profitable? | No, Autolus Therapeutics is not profitable. |
| What is the current EBITDA of Autolus Therapeutics? | Autolus Therapeutics has negative EBITDA and is not profitable. |
| What is Autolus Therapeutics' EBITDA margin? | Autolus Therapeutics' last 12 months EBITDA margin is (287%). |
| What is the current EV/EBITDA multiple of Autolus Therapeutics? | Current EBITDA multiple of Autolus Therapeutics is (0.4x). |
| What is the current FCF of Autolus Therapeutics? | Autolus Therapeutics' last 12 months FCF is ($219M). |
| What is Autolus Therapeutics' FCF margin? | Autolus Therapeutics' last 12 months FCF margin is (247%). |
| What is the current EV/FCF multiple of Autolus Therapeutics? | Current FCF multiple of Autolus Therapeutics is (0.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.